Skip to content

Author

Jae H. Park

We have 3 of 36 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Respiratory Viral Infections Following CAR-T Cell Therapy for Lymphoma and Myeloma: Severity and Immune Correlates.

BACKGROUND Infectious complications are a major cause of morbidity and non-relapse mortality after CAR-T cell therapy. Respiratory viral infections (RVIs) are frequent, yet their incidence, timing, and immune correlates remain incompletely defined. METHODS We retrospectively analyzed laboratory-confirmed RVIs in 563...

S. Einarsdottir, Teng Fei, M. Sotelo-Alva et al. · 0 citations
Aug 2026

Tumor CD19 Expression Determines Distinct Clinical Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

It remains uncertain whether lower CD19 expression is clinically relevant for outcomes of CD19 CAR-T therapy of large B-cell lymphoma (LBCL). We conducted an integrative analysis of tumor CD19 levels with centralized quantitative assessment by flow cytometry (FC), immunohistochemistry and RNA-sequencing in a LBCL cohor...

M. Corona, Aaron Gillmor, K. Argyropoulos et al. · 0 citations
Open access Jul 2026

IL7-Receptor–Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia

The authors propose IL7-Receptor (IL7R/CD127) as an alternative target for T-ALL and propose IL7-Receptor/CD127 CAR-T cells as an alternative target for T-ALL, showing the antitumor efficacy of IL7Rα/CD127 CAR-T cells against T-ALL in preclinical models.

H. Hocine, Undrakh Ganbaatar, Alfredo Amador-Molina et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.